Urbanska et al. [112] hypothesized that targeting FSHR in cancerous tissue, FSHR+ tumor vasculature, and FSHR+ reproductive tissue that is otherwise healthy yet non-essential for patient survival will create an attractive avenue for CAR therapy. The gene discussed is FSHR; the disease is neoplasm.